Vitamin D3 for Life

Live Enlightened

Article

Intestinal VDR, Barrier Function and Microbial Metabolism: Full Evidence Review

Previous related pageVitamin D and Mucosal DefenceNext related pageIntestinal VDR, Barrier Function and Microbial Metabolism: Study Summary
Study at a glance

How were vitamin D signals, the gut lining and gut microbes studied?

This review combines cell and animal experiments with two small human trials. Researchers examined vitamin D signals, the intestinal lining, gut microbes and their products. Some experiments removed the vitamin D receptor or used active hormone or a receptor-activating drug. The human trials gave vitamin D3 supplements. These different tests test different parts of the system.

How did vitamin D signals affect the gut lining in animals?

In mouse models, low vitamin D or receptor loss worsened intestinal injury caused by chemicals and increased passage of a test substance through the lining. Other experiments found protective responses with receptor activation. In injured rats, active vitamin D improved selected measurements of cell replacement and how easily substances passed through the intestinal lining. Changes in proposed chains of signals inside cells supported possible explanations, but did not prove every step was necessary.

Did supplements improve the gut lining or microbes in people?

A trial of 27 people with Crohn’s disease in remission found no clear supplement-versus-placebo improvement in permeability (how easily substances passed through the intestinal lining), inflammatory markers, disease activity or quality of life. A separate trial in mostly young, healthy adults found some changes in gut microbes. It did not establish a healthier community of gut microbes, better barrier function or less inflammation throughout the body.

Do these studies show one proven route to better gut health?

Small samples and differences between models limit comparison. More protein at the joins between cells does not by itself prove a barrier that lets less through, and one set of measurements of labelled cells does not measure the entire replacement process. The healthy-adult trial also had differences in gut microbes at the start and gummies with other differing ingredients. Together, the studies do not demonstrate that supplements improve microbes, the intestinal barrier and inflammation throughout the body through one proven chain of effects.

Read the full article below ↓

Experiments connect intestinal vitamin D signalling with junction organisation, epithelial renewal and microbial metabolism. Small human trials test different parts of that relationship, with less consistent functional results. This review separates direct barrier measurements from molecular markers and proposed systemic effects. For the companion appraisal, see Intestinal VDR, Barrier Function and Microbial Metabolism: Study Summary.

Barrier function requires more than a protein marker

Li and colleagues examined vitamin D deficiency, whole-body VDR deletion and activation of the receptor in mouse colitis and epithelial models. Their experiments contribute to Vitamin D and Gut by measuring tracer permeability as well as tight-junction proteins. A junction-protein image indicates organisation or abundance; passage of a tracer across the intestinal barrier supplies a distinct functional observation.

Mice fed a vitamin D-deficient diet for twelve weeks, and mice lacking VDR, were more susceptible to chemically induced colitis than their respective controls. Disease activity and histological injury increased, alongside higher blood concentrations of a fluorescent dextran permeability tracer. Claudin-1 and claudin-3 staining was disrupted. The receptor-knockout mice received a mineral-rescue diet, but whole-body deletion still cannot isolate an exclusively epithelial mechanism.

Notch signalling provides a candidate connection

The study measured Notch-1, its cleaved intracellular domain and the downstream regulator Hes1. Receptor loss or reduced vitamin D availability was accompanied by lower Notch-related measurements under the tested conditions. A gamma-secretase inhibitor used to suppress Notch activation worsened colitis and barrier injury. These perturbations support a functional connection, but the inhibitor is not a selective genetic test of every proposed step.

In cultured Caco-2 cells, the VDR agonist paricalcitol altered Notch and junction-protein measurements. Inhibition of Notch restricted the response, particularly the claudin-3 response; the images do not support a claim that every claudin-1 response vanished. Organoids from VDR-knockout mice provided another epithelial comparison, with lower Notch-related and junction measurements. The evidence therefore supports partial pathway dependence rather than a single exclusive mechanism.

A Notch-1 promoter reporter responded to receptor overexpression and agonist exposure. Predicted VDR-binding sequences supplied a hypothesis about the regulatory region. A reporter result and a sequence prediction do not directly demonstrate VDR occupancy at the native promoter. The authors identified chromatin-immunoprecipitation and further rescue experiments as useful next steps. Vitamin D and Gene Expression explains the difference between an expression response and a completed direct-binding mechanism.

Inflammation changes the meaning of a signalling response

Notch-related activity also increased during inflammatory stimulation even while junction injury persisted. Activation cannot consequently be equated with complete protection in every setting. The proposed interpretation is a response that may be protective yet insufficient to prevent injury. For Vitamin D and Inflammatory Signalling, this is a reason to measure the tissue outcome alongside a pathway marker.

Paricalcitol-treated mice showed less severe injury and partial recovery of junction staining. Treatment began before the chemical challenge; this was not correction of an established human disease with ordinary vitamin D3 tablets. The agonist experiment also used a longer challenge schedule, visible in the supplementary timeline, than the seven-day deficiency and knockout comparisons. Small groups, different experimental arms and selected injury models restrict direct comparisons across the paper.

Tissue-specific receptor loss alters microbial metabolites

Chatterjee and colleagues examined mice with VDR deleted in intestinal epithelial cells or in myeloid cells. Those interventions act at different parts of Vitamin D and Immune Modulation. They compared faecal metabolites and microbial measurements with receptor-intact controls, and separately tested a high-fat diet in epithelial-knockout and control mice. This was not a vitamin D supplementation study.

The metabolite profiles differed by tissue-specific genotype, diet and sex. Diet produced particularly strong separation in the broad profile analysis. The chow groups contained seventeen epithelial-knockout, ten myeloid-knockout and sixteen control mice; high-fat comparisons were smaller. Results from these groups should not be treated as a universal microbial fingerprint of low blood vitamin D in people.

Selected Parabacteroides measurements were lower with epithelial VDR deletion, while the corresponding myeloid comparisons did not show the same pattern. Some other bacterial differences were trends rather than statistically established changes. Relative abundance does not determine absolute bacterial counts, and neither the presence nor absence of one taxon defines a healthy community. The receptor context described in Vitamin D Receptors must remain separate from a claim that supplements restore a desirable microbiome.

Metabolite patterns do not prove systemic inflammatory mediation

The study also reported altered bile-acid-related metabolites and higher FXR protein measurements in colon and liver under selected conditions. These observations motivate a gut: liver signalling hypothesis. They do not show that a particular microbial product caused systemic inflammation or that modifying that product would improve a clinical outcome. Faecal concentrations reflect production, consumption, absorption and transit; they are not a direct measurement of circulating exposure or metabolic flux.

The extensive metabolite screen is exploratory. Some captions describe probabilities between 0.05 and 0.10 as significant, and the Results and Discussion disagree about the direction of selected metabolites. Those directions should not become mechanistic anchors. The authors themselves identified sample-matched microbial-function analysis, plasma measurements and validation in human cohorts as further work. The connection to Vitamin D and Mucosal Defence is therefore a set of testable host: microbe relationships, not established infection protection.

Direct evidence about epithelial renewal

Junction organisation and microbial metabolite profiles do not establish how epithelial cells are replaced. Wang and colleagues addressed that separate question in male rats with carbon-tetrachloride-induced liver injury. Four groups of eight animals compared sham treatment, calcitriol alone, the injury model, and injury plus calcitriol. This was administration of the active hormone, not an oral vitamin D3 supplementation trial.

The investigators measured proliferating-cell nuclear antigen, or PCNA, in intestinal crypts, and used TUNEL staining to assess DNA fragmentation associated with apoptosis. Injury reduced the crypt proliferation measurements and increased the apoptotic index. Calcitriol partly reversed these changes. The combined endpoints are more informative for epithelial renewal than a junction-protein measurement alone.

A separate pulse of BrdU labelled cells synthesising DNA. Six hours later, the researchers counted labelled cells along basal, middle and upper regions of the crypt: villus axis. Injured animals had fewer labelled cells in the measured basal and middle regions; the calcitriol-treated injury group had higher counts. This supports an effect on renewal-related cell distribution under those conditions. A single six-hour snapshot cannot establish the entire replacement rate or independently separate proliferation from migration.

The paper’s abstract and methods disagree about the treatment chronology, so a single exact schedule cannot be treated as resolved. The study also used one sex, one chemical injury model and small groups. Effects on the liver and the intestine occurred together; the design does not isolate a direct epithelial action from improvement elsewhere in the injured animal.

Physical permeability and the proposed HO-1 mechanism

Wang’s study also measured ZO-1 and occludin, proteins associated with tight junctions. Their injury-related reductions were attenuated with calcitriol. Biotin-tracer movement through colonic tissue and leakage of an intestinal fluorescein-labelled dextran into blood were reduced in the treated injury group. These functional permeability tests complement the protein measurements; the proteins alone would not establish barrier exclusion.

Cultures of sampled organs and lymph nodes supplied a separate bacterial-translocation endpoint. Calcitriol reduced positive cultures in the injured animals, while blood cultures were negative in all groups. This is not evidence that a specific microbial community was restored, nor does it establish that the bacteria or their products caused every measured liver or intestinal change.

Heme oxygenase-1, abbreviated HO-1, was increased with calcitriol, alongside changes in oxidative-stress markers. The authors proposed mediation through HO-1, but did not inhibit or silence it. Increased expression accompanying an improved phenotype is not a causal mediation test. The Results and Figure 7 also describe a slight injury-related increase in HO-1, whereas the Discussion describes a decrease. The mechanism should remain a hypothesis, without using the inconsistent baseline direction as established evidence.

Human supplementation and systemic markers

Raftery and colleagues randomised 27 people with Crohn’s disease in remission to 2,000 IU/day vitamin D3 or placebo for three months. At follow-up, the groups did not differ significantly in measured permeability, LL-37, CRP, faecal calprotectin, disease activity or quality of life. Permeability increased within the placebo group but remained stable within the treatment group; those separate comparisons do not establish a treatment effect. A secondary grouping by achieved vitamin D concentration associated higher status with lower CRP and higher LL-37 and quality-of-life scores. That comparison no longer preserves randomisation and does not establish an effective blood-level target.

CRP is a circulating inflammatory marker; faecal calprotectin reflects an intestinal inflammatory measurement; LL-37 is a cathelicidin-derived antimicrobial peptide. These outcomes address different parts of the proposed pathway. A change in one would not establish that the others changed, and a within-group before-and-after comparison cannot replace the randomised between-group contrast. The small trial leaves considerable uncertainty about modest effects and narrower patient groups.

Human microbiome measurements

Wyatt and colleagues provide a different human comparison. They randomised 43 mostly young, healthy adults to vitamin D3 or placebo and analysed 41. Stool samples at four time points showed changes in community similarity and particular taxa, while diversity within the treated participants did not significantly increase. An early Bifidobacterium difference was not significant against placebo at the final assessment. The results therefore qualify a uniformly null account of human microbiome responses, but do not establish a healthier community or reduced systemic inflammation.

Interpretation is limited by baseline microbial differences and intervention gummies that differed in ingredients beyond vitamin D. The Methods and supplementary schedule describe twelve weeks of supplementation, whereas other passages discuss persistence after stopping at fourteen days. That inconsistency prevents a firm post-withdrawal claim. This small trial measured microbial and metabolic patterns; it did not demonstrate improved barrier function or cancer prevention.

How the models fit together

These clinical comparisons help distinguish a receptor-deletion mechanism from the effect of changing nutrient availability. A receptor perturbation and a supplement assignment act at different points in the biological system. They can produce different results without invalidating either experiment. The appropriate translation is a testable question about which patients, exposures and outcomes might reproduce a particular mechanism.

Vitamin D and Inflammatory Signalling provides the context for distinguishing a local intestinal cytokine from a circulating inflammatory marker. Neither is a complete measure of inflammation throughout the body. Likewise, a change in microbial composition does not establish that the organisms caused a change in host physiology. That causal claim needs evidence linking a defined microbial activity to a measured host response.

Direct renewal and permeability findings come from injured rats receiving calcitriol. The Notch and tracer experiments address barrier organisation in mouse and epithelial models, while conditional receptor deletion supplies separate microbial and metabolite evidence. The human studies changed vitamin D availability and measured selected clinical or biological outcomes. These are complementary tests within Vitamin D and Barrier Immunity, but they are not independent replications of one intervention or one complete causal pathway.

Conclusion

The experimental evidence supports roles for epithelial vitamin D signalling in cellular maintenance, renewal-related measurements and barrier organisation under defined conditions. Human studies considered here do not establish a supplementation-driven improvement in microbiota, permeability and systemic inflammation as a single clinical chain. The proposed HO-1, Notch and microbial-metabolite mechanisms remain more limited than that broader claim.

Sources and publication details

Vitamin D/vitamin D receptor protects intestinal barrier against colitis by positively regulating Notch pathway. Li Y and colleagues. Frontiers in Pharmacology. 2024;15:1421577. DOI: 10.3389/fphar.2024.1421577. PMID: 39130644.

Vitamin D receptor promotes healthy microbial metabolites and microbiome. Chatterjee I and colleagues. Scientific Reports. 2020;10:7340. DOI: 10.1038/s41598-020-64226-7. PMID: 32355205.

Vitamin D Improves Intestinal Barrier Function in Cirrhosis Rats by Upregulating Heme Oxygenase-1 Expression. Wang P and colleagues. Biomolecules & Therapeutics. 2019;27(2):222 to 230. DOI: 10.4062/biomolther.2018.052. PMID: 30173501.

Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. Raftery T and colleagues. United European Gastroenterology Journal. 2015;3(3):294 to 302. DOI: 10.1177/2050640615572176. PMID: 26137304.

Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults. Wyatt M and colleagues. Microbiology Spectrum. 2024;12(10):e00083-24. DOI: 10.1128/spectrum.00083-24. PMID: 39189761.

Related reading

Original sources

Source

Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study

Published in Raftery T and colleagues. United European Gastroenterology Journal (2015).

Publication details

Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study. Raftery T and colleagues. United European Gastroenterology Journal. 2015;3(3):294 to 302. DOI: 10.1177/2050640615572176. PMID: 26137304.

Read more →
Source

Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults

We conducted a double-blind, randomized, placebo-controlled trial to identify the acute and long-term microbiota structural and metabolite changes that occur in response to a moderate dose (4,000 IU) of vitamin D3 for 12 weeks in healthy adults.

Publication details

Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults. Wyatt M and colleagues. Microbiology Spectrum. 2024;12(10):e00083-24. DOI: 10.1128/spectrum.00083-24. PMID: 39189761.

Read more →